title: Polymorphisms in the advanced glycosylation end product-specific receptor gene and risk of incident myocardial infarction or ischemic stroke.
abstract: OBJECTIVE
  Recent findings of an association between polymorphisms of advanced glycosylation end product-specific receptor (AGER) and risk of diabetic vasculopathy have generated great interest. However, to date, no genetic-epidemiological data are available on risk of atherothrombotic events among nondiabetic populations.
  
  
  METHODS
  Using DNA samples collected at baseline in a prospective cohort of 14,916 initially healthy American men, we evaluated 3 AGER genetic variants: -429T>C, -374T>A, and Gly82Ser, among 600 white individuals who subsequently developed atherothrombotic event (incident myocardial infarction or ischemic stroke) and among 600 age- and smoking-matched white individuals who remained free of reported vascular disease during follow-up (controls).
  
  
  RESULTS
  Genotype distributions for the polymorphisms tested were in Hardy-Weinberg equilibrium. Haplotype-based conditional logistic regression, adjusting for other potential confounders, showed that haplotype C-T-Gly (myocardial infarction: odds ratio [OR], 0.60; 95% CI, 0.41 to 0.90; P=0.01) and haplotype T-A-Gly (ischemic stroke: OR, 0.63; 95% CI, 0.40 to 0.99; P=0.05), compared with the reference haplotype T-T-Gly, were associated with reduced risk of atherothrombosis. Prespecified analysis limited to those without baseline history of diabetes showed similar significant findings.
  
  
  CONCLUSIONS
  We found an association of specific AGER promoter gene haplotypes with reduced risk of incident myocardial infarction and ischemic stroke that was independent of the presence of diabetes.
authors.affiliation: Center for Cardiovascular Disease Prevention, the Donald W. Reynolds Center for Cardiovascular Research, the Leducq Center for Molecular and Genetic Epidemiology, Boston, Mass, USA. rzee@rics.bwh.harvard.edu
authors.forename: Robert Y L
authors.initials: RY
authors.lastname: Zee
authors.forename: Jose R
authors.initials: JR
authors.lastname: Romero
authors.forename: Jessica L
authors.initials: JL
authors.lastname: Gould
authors.forename: Dennis A
authors.initials: DA
authors.lastname: Ricupero
authors.forename: Paul M
authors.initials: PM
authors.lastname: Ridker
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019943:Amino Acid Substitution; D050197:Atherosclerosis / Q000453:epidemiology*; D002545:Brain Ischemia / Q000453:epidemiology*; D016022:Case-Control Studies; D015331:Cohort Studies; D015897:Comorbidity; D004252:DNA Mutational Analysis; D004311:Double-Blind Method; D005838:Genotype; D006239:Haplotypes / Q000235:genetics; D006801:Humans; D008297:Male; D008875:Middle Aged; D020125:Mutation, Missense; D009203:Myocardial Infarction / Q000453:epidemiology*; D010820:Physicians; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic / Q000235:genetics*; D012306:Risk; D012907:Smoking / Q000453:epidemiology; D014481:United States / Q000453:epidemiology; D044465:White People / Q000235:genetics
chemical_list: D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic